Introduction
Pancreatic cancer remains one of the most lethal human cancers. This is due, in part, to resistance to most chemotherapeutic drugs. The nucleoside pyrimidine analog gemcitabine is the most effective single agent in the palliation of advanced pancreatic cancer, in which it has been shown to improve clinical symptoms and modestly extend survival. 1 Gemcitabine is also approved for use in non-small cell lung cancer, breast cancer and ovarian cancer. However, the use of gemcitabine can be associated with significant dose limiting toxicity, especially hematologic. Predicting response to gemcitabine in pancreatic cancer treatment would have significant impact in deciding which patients should receive this agent. Furthermore, predicting toxicity to gemcitabine in pancreatic cancer would enable clinicians to either reduce the dose or consider alternate treatment regimens.
It is likely that genetic variability of key enzymes in gemcitabine transport and metabolism may impact on treatment response and toxicity of gemcitabine agents. 2 Cytidine deaminase (CDA) is the key enzyme responsible for the inactivation of gemcitabine after it has been transported into the cell before phosphorylation. One polymorphism in the CDA gene, CDA Lys 27 Gln, has been proposed as being a predictor of gemcitabine treatment response and toxicity. However, the data is inconclusive and conflicting. In a recent prospective non-randomized clinical pharmacogenomic study among non-small cell lung cancer patients treated with cisplatin plus gemcitabine, the CDA Lys 27 Lys polymorphism genotype significantly correlated with improved clinical benefit, worse hematological toxicity, including neutropenia and thrombocytopenia, as well as longer time to progression and overall survival (OS) than the other CDA genotypes. 3 In a more recent non-randomized, retrospective larger study of 149 patients with locally advanced pancreatic cancer patients receiving combinations of gemcitabine and platinum drugs, the CDA Lys 27 Lys polymorphism was associated with less hematological toxicity and no survival benefit compared with patients with either the CDA Lys 27 Gln or CDA Gln 27 Gln genotype. 4 However, other data does not find an association between this CDA polymorphism and treatment outcome with gemcitabine. 5, 6 The Radiation Therapy Oncology Group (RTOG) 9704 study is a phase III randomized post-operative adjuvant study in patients after resection of pancreatic cancer comparing pre-and post-chemoradiation 5-FU with preand post-chemoradiation 5-fluororuacil and gemcitabine. 7 It represents a unique tool to validate markers predictive of gemcitabine treatment response and toxicity. We used pretreatment resected tumors from patients enrolled in this study to analyze this CDA Lys 27 Gln polymorphism and correlate it with patient demographics and treatment outcome, including toxicity.
Patients and methods

Patient selection and consent
Patients entering RTOG 9704 gave consent for use of formalin-fixed tissue for translational research as part of the formal informed consent process. Blood or buccal swabs were not available as part of this protocol. The RTOG tissue bank received tumor blocks from a total of 229 of the 538 patients who had undergone surgical resection and were entered in the RTOG 9704 prospective adjuvant treatment trial. Clinicopathological factors were obtained as part of the enrollment of the patients in the study. Treatment schedules and follow-up clinical information including outcome (OS, disease free survival) and toxicity was recorded as end points in the study. Permission to conduct this study was obtained by the University of California, Los Angeles, Institutional Review Board.
RTOG 9704
RTOG 9704 was a randomized, phase III intergroup study run by the RTOG in association with the Eastern Cooperative Oncology Group and the Southwest Oncology Group under the auspices of the Cancer Therapy Evaluation Program of the National Cancer Institute. The primary results of this randomized trial have been reported. 7 In this trial patients undergoing surgery with curative intent for resectable pancreatic adenocarcinoma were randomized to receive either continuous infusion 5-FU or intravenous gemcitabine before and after 5-FU and radiotherapy (RT). A total of four cycles of gemcitabine were administered, with each cycle consisting of gemcitabine (1000 mg m À2 per week) three weeks out of four. The rationale for this study has been previously described and discussed. 8 CDA single-nucleotide polymorphism (SNP) genotyping DNA for SNP genotyping was extracted from patient pancreatic cancer tumor cores following the manufacturer's instructions (Qiagen, Valencia, CA, USA) and as previously described. An Illumina GoldenGate assay (Illumina, San Diego, CA, USA) was used to genotype the CDA polymorphism. 9, 10 This technology has a concordance, reproducibility and call rate 499.5%. CDA Lys
27
Gln polymorphism genotyping has three potential results: most frequent homozygous (homozygote wild-type reference, Lys/Lys), heterozygous (Lys/Gln) and least common homozygous (homozgote variant, Gln/Gln).
Outcome measures
The failure event for OS was defined as death due to any cause. Survival time was measured from the date of randomization to the date of death or last follow-up. The failure event for disease-free survival (DFS) was defined as disease relapse (local or regional), distant disease (including abdominal ascites, peritoneal seeding and other abdominal sites), second primary or death due to any cause. Time to DFS was measured from the date of randomization to the date of first disease-free failure event occurrence. Toxicities were graded using the common toxicity criteria version 2.0 criteria for systemic therapy and the RTOG morbidity scoring scheme for radiation. The following three toxicities were analyzed; the worst severe overall, the worst severe hematological and the worst severe non-hematological toxicity. The toxicity greater than or equal grade 3 was defined as severe toxicity. The individual events and the individual frequencies contributing to each of the three toxicities were not available for analysis. Further data on whether these toxicities were asymptomatic or resulted in treatment delay or dose modification is not available for this analysis.
Statistical analysis
The potential three genotype expressions for a CDA Lys 27 Gln polymorphism were used: most frequent homozygous (homozygote wild-type reference, Lys/Lys), heterozygous (Lys/Gln) and least common homozygous (homozygote variant, Gln/Gln, reference level (RL)). SNP genotype expression was also analyzed as a dichotomized variable, the homozygote reference combined with the heterozygous SNP and the homozygote variant SNP (Lys/ Lys or Lys/Gln) versus Gln/Gln (RL)). The variant genotype was used as the RL in order to allow for comparison with previous CDA Lys 27 Gln polymorphism genotype analysis. 3 The following covariates were adjusted for the multivariate analyses; age (continuous), gender (male (RL) versus female), race (White (RL) versus non-White), primary tumor location (head (RL) versus other), American Joint Committee on Cancer stage (I, II (RL) versus III, IV), surgical margin status (negative (RL) versus positive versus unknown), primary tumor diameter (o3 cm (RL) versus X3 cm), Karnofsky performance scale (60-80 (RL) versus 90-100). We chose these co-variates for the multivariate analysis based on their significance in this study (for example, tumor size) and the original RTOG 9704 clinical study. 7 The w 2 -test statistics were used for the comparison of the distribution of genotype and for assessing whether missing SNP data were associated with baseline characteristics. The Hardy-Weinberg equilibrium assumption was checked with Fisher's exact test statistics. 11 The OS and DFS outcome were considered in two ways: time to failure event and outcome status at 18 months.
Cox proportional regression models were applied to test the association between time to failure event and CDA polymorphism genotype with and without adjustment for the covariates above.
12 Logistic regression models were used for toxicity and outcome status at 18 months and CDA genotype with and without adjustment for the covariates. 13 All two-sided tests were carried out at a significance level of 0.05. Statistical Analysis System (SAS Institute, Cary, NC, USA) and Software R (R Foundation, Vienna, Austria) were used for all analyses. The analyses were carried out in each arm separately.
Power calculation was based on the main study hypothesis and was performed using the logistic regression module of Sample Power software (SPSS, Chicago, IL, USA). It showed that with a sample size of 150 (50% from each treatment arm), the study had 480% power to detect an odds ratio (OR) of 0.5 for the CDA Lys27Gln polymorphism at a significance level a ¼ 0.05 (two-sided), assuming a dominant mode of gene inheritance and that the frequency of the variant allele in both arms is 45%.
Results
Pretreatment characteristics
The study opened 20 July 1998 and closed on 26 July 2002 with a total of 538 patients, 268 of whom were randomized to the RT þ gemcitabine arm. Of the 268 patients entered on the RT þ gemcitabine arm, 47 were ineligible for analysis because of the main RTOG 9704 trial exclusion criteria. 7 Of the remaining cases in this group, 87 were eligible and had analyzable CDA Lys 27 Gln polymorphism genotype. Of the 230 patients entered on the RT þ 5-FU arm, 39 were ineligible for analysis because of the main RTOG 9704 trial exclusion criteria. 7 Of the remaining cases in this group, 98 were eligible and had analyzable CDA Lys 27 Gln polymorphism genotype. The results of w 2 -test show that none of the pretreatment characteristics were statistically unbalanced between the missing and determined CDA Lys 27 Gln polymorphism genotype patients groups in either the RT þ gemcitabine arm or the RT þ 5-FU arm (Table 1) .
CDA Lys
27 Gln polymorphism genotype The no call rate for all polymorphisms was o4%. For the CDA Lys
27
Gln polymorphism genotyping, the homozygous wild type (Lys/Lys) was found in 39.5%, whereas the heterozygous (Lys/Gln) and homozygous variant (Gln/Gln) was found in 50.2% and 10.3%. The CDA Lys 27 Gln polymorphism genotype followed Hardy-Weinberg equilibrium assumption (P ¼ 0.57) among both treatment arm groups, and the genotype frequencies of CDA Lys 27 Gln polymorphism were similar to those in a control and nonsmall cell lung cancer Caucasian population.
3,14
Pretreatment characteristics and CDA Lys 27 Gln genotype CDA Lys 27 Gln polymorphism genotyping for all patients enrolled in the study are presented in Table 2 . Although 229 patients had CDA genotype available, only 185 were included in the final analysis because of the exclusion criteria as outlined above. The only statistical associations between CDA Lys 27 Gln SNP genotype and baseline demographics were for primary tumor dimension (P-value ¼ 0.005) and primary tumor location (P ¼ 0.04) in the RT þ gemcitabine arm, which were included in the multivariate analysis. There are no statistical associations between CDA Lys 27 Gln polymorphism genotype and pretreatment characteristics in the RT þ 5-FU arm.
Correlation between CDA Lys 27
Gln polymorphism and clinical outcome The results of w 2 -test show that there were no survival outcome differences between patients with missing and determined CDA Lys 27 Gln polymorphism genotype. No statistical differences were found between CDA Lys 27 Gln polymorphism genotype and survival outcome in all patients, as well as for patients in either the RT þ gemcitabine arm or the RT þ 5-FU (Table 3) . For 35 patients carrying CDA Lys/Lys polymorphism genotype in the RT þ gemcitabine arm, the overall median survival time is 1.57 years (range: 0.33-6.17 years). This group has a better treatment outcome compared with the 43 patients carrying CDA Lys/ Gln and the 9 patients carrying CDA Gln/Gln polymorphism genotype: overall median survival of 1.24 years (range: 0.42-5.98 years) and 1.41 years (range: 0.32-4.7 years). However, there is no statistically significant difference in survival (OS, DFS, OS at 18 months, DFS at 18 months) when comparing the three CDA genotypes alone (Lys/Lys versus Lys/Gln versus Gln/Gln) or dichotomized genotypes (Lys/Lys or Lys/Gln versus Gln/Gln; Gln polymorphism genotype with worst severe (defined as grade 3 or 4 toxicity) overall, hematological and non-hematological toxicity are shown in Table 4 . For the RT þ gemcitabine arm, there is a statistically significant difference with respect to worst hematological toxicity between the patients with homozygote wild-type CDA genotype (Lys/Lys; adjusted OR ¼ 0.06, P-value ¼ 0.01) and borderline significance between patients with heterozygote CDA genotype (Lys/Gln; adjusted OR ¼ 0.17, P-value ¼ 0.06) when compared with homozygote variant CDA genotype (Gln/Gln) when adjusted for other covariates. This holds when patients whose CDA genotype is homozygote wild type (Lys/Lys) or heterozygote (Lys/Gln) are compared with homozygote variant (Gln/Gln; adjusted OR ¼ 0.14, P-value ¼ 0.03). However, this association between CDA genotype and severe hematological toxicity is not seen in patients in the RT þ 5-FU arm who did not receive gemcitabine. Associations between CDA genotype and either worst overall toxicity or worst non-hematological toxicity were not seen in either treatment arm.
Discussion
Our data uses larger prospectively controlled randomized phase III clinical trials to confirm an association between the homozygous wild-type CDA Lys 27 Lys polymorphism, either alone or in combination with the heterozygote CDA Lys 27 Gln genotype, and severe hematological toxicity when compared with the homozygote CDA variant Gln 27 Gln genotype in patients receiving gemcitabine but not in patients receiving 5-FU. No association between CDA genotype and treatment outcome (either OS or DFS) was seen in our study in either group, although the nonstatistically significant longer survival for the Lys
27
Lys group is noted. Although there are differences with respect to tumor size between the groups studied, this should not impact on hematological toxicity during treatment. Thus, co-variates for multivariate analysis were selected based on their significance in this study (for example, tumor size) and the original RTOG 9704 clinical study. 7 Overall, the data suggests the CDA Lys 27 Gln polymorphism genotype is a predictive marker of gemcitabine-associated hematological toxicity. The metabolic inactivation of gemcitabine is catalyzed by CDA, or after phosphorylation, by deoxycytidylate deaminase. However, the relationship between CDA activity and gemcitabine sensitivity and toxicity is not clear. In solid tumor cell lines, CDA activities with gemcitabine as substrate vary considerably (20-to 30-fold). 15 Only cells transfected with CDA are less sensitive to gemcitabine suggesting the need for very high levels of CDA activity. 16 However, clinical studies show a correlation between mRNA expression of CDA in peripheral blood mononuclear cells and clinical outcome in gemcitabine-treated patients, 17 and CDA gene expression in bone marrow mononuclear cells and hematological toxicity. 18 Similarly, the pharmacogenomics of deamination, including CDA polymorphisms, is conflicting. A total of 17 polymorphisms in the CDA gene, including the one common non-synonymous SNP studied in this current paper, CDA Lys 27 Gln, were identified in a study of 60 19 This is supported by other in vitro studies using cytarabine (ara-C) as substrate at concentrations of 1 Â 10 À8 -2 Â 10 À2 M, with the recombinant CDA Lys 27 Lys enzyme exerting a 1.3-to 3.3-fold higher in vitro deamination rate of ara-C than the variant CDA Gln 27 Gln enzyme. 20 However, in other in vitro studies, it is another non-synonymous CDA SNP, CDA Ala 70 Thr polymorphism, which shows 40% and 32% activity of wild type for cytidine and ara-C substrates, respectively. However, sensitivity to cytarabine was not changed by introducing homozygous variant CDA Gln 27 Gln polymorphism in this in vitro model. 21 We were unable to assess CDA enzymatic activity using blood samples and correlate it with CDA genotype in this study.
Previous clinical data has supported the significance of this other CDA Ala
70
Thr polymorphism, in which a patient with a homozygous variant showed severe adverse reactions with an increase in gemcitabine plasma level. 22 The same group also suggested that this CDA Thr 70 Thr polymorphism is associated with survival in patients with pancreatic cancer. 23 In a prospective pharmacokinetic study investigating the effects of CDA genetic polymorphisms on gemcitabine pharmacokinetics and toxicities in 256 patients receiving a 30-min intravenous infusion of gemcitabine at a dose of either 800-or 1000 mg m À2 , the influence of 26 genetic variations in the CDA gene, including 14 novel ones and the two known non-synonymous CDA Lys Thr polymorphic variant, this haplotype has a frequency of only 3.7% in the Japanese population and has yet to be detected in Caucasians.
14 In fact, the frequency of homozygous variant CDA Gln 27 Gln in this study was 21%, making it a more common and clinically relevant CDA polymorphism. This was further argued by a French group who described severe hematological toxicity in 4 of 80 patients, which correlated with markedly lower CDA activities than those in the 76 patients showing good gemcitabine tolerance. None of the four toxic patients exhibited the CDA Thr 70 Thr polymorphism. 25 In a follow-up study on one patient with several gemcitabine toxicity studied by the same group, marked CDA deficiency was associated with heterozygosity for the CDA Lys 27 Gln polymorphism, whereas surprisingly the CDA Ala 70 Thr polymorphism was not found. 26 This observation was felt to be consistent with other observations describing controversies regarding genotype to phenotype associations with CDA. 20, 25 In a small clinical study among non-small cell lung cancer patients treated with cisplatin plus gemcitabine, the homozygous wild-type CDA Lys 27 Lys genotype predicted a better clinical benefit, grade 3 or higher neutropenia or thrombocytopenia, longer time to progression and overall survival than the other CDA genotypes (Table 5) . At multivariate Cox regression analysis, the polymorphism of CDA Lys
27
Gln remained an independent predictive variable of treatment efficacy. Moreover, the trend toward correlation with response suggests that CDA Lys 27 Lys may be a predictive factor of treatment activity and not only a prognostic factor of outcome. 3 The same study showed a significant correlation between the homozygous wild-type CDA Lys 27 Lys genotype and lower CDA enzymatic activity, compared with the other genotypes. 3 These data seemed to be in agreement with an in vitro study, which suggests a high correlation between very high levels of CDA and resistance to gemcitabine. 16 Although this paper appears to show least toxicity in the CDA Lys 27 Gln, rather than the CDA Gln 27 Gln, which would be counterintuitive, it is unclear if this difference is statistically significant. However, in a more recent non-randomized, retrospective larger study of 149 patients with locally advanced pancreatic cancer receiving combinations of gemcitabine and platinum drugs, the CDA Lys 27 Lys polymorphism was actually associated with less hematological toxicity and no survival benefit compared with patients with either the CDA Lys 27 Gln or CDA Gln 27 Gln genotype (Table 5) . 4 In contrast to this paper, our data, using prospectively collected information and a treatment arm using gemcitabine solely appears to suggest the importance of the CDA Lys 27 Lys genotype in predicting hematological toxicity, but raises concerns about whether or not this SNP is predictive of treatment response (Table 5) . In fact other studies have not found an association between this CDA Lys 27 Gln polymorphism and treatment outcome after treatment with nucleoside analogs. 5, 6 One limitation of our study is the absence of more detailed information on the individual events and frequencies contributing to the severe hematological toxicity, including whether or not they were asymptomatic or contributed to dose modification or treatment delay.
In summary, our larger prospectively collected data from a randomized clinical trial, in which one arm received gemcitabine and the other did not supports the hematological toxicity predictive value of the non-synonymous CDA Lys 27 Gln polymorphism while not finding an association between this polymorphism and other non-hematological toxicity or treatment outcome. As the hematological toxicity of gemcitabine is a real clinical problem, the clinical use of this polymorphism may prove helpful in stratifying patients with all stages of pancreatic cancer to receive different dosing regimens of gemcitabine or be monitored differently. For example, it may be possible to increase the dose of gemcitabine or even consider co-administration of other hematological toxic agents in patients with the Gln/ Gln polymorphism. Abbreviations: CDA, cytidine deaminase; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; SNP, single-nucleotide polymorphism.
